Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chiglitazar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 20/20 | 0.65 |
| ▸ | PPARA known ✓ | Q07869 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carfloglitazar SCHEMBL29353776 | 1.00 | PPARG (0.65) | PPARGPPARA | |
| Carfloglitazar SCHEMBL10084143 | 1.00 | PPARG (0.65) | PPARGPPARA | |
| Chiglitazar SCHEMBL22607975 | 1.00 | PPARG (0.65) | PPARGPPARA | |
| SCHEMBL21565295 | 0.97 | PPARG (0.62) | PPARGPPARA | |
| SCHEMBL2787981 | 0.94 | PPARG (0.71) | PPARGPPARA | |
| SCHEMBL6637182 | 0.94 | PPARG (0.71) | PPARGPPARA | |
| SCHEMBL21565294 | 0.93 | PPARG (0.59) | PPARGPPARA | |
| SCHEMBL14274956 | 0.92 | PPARG (0.76) | PPARGPPARA | |
| SCHEMBL24659891 | 0.91 | PPARG (0.54) | PPARGPPARA | |
| SCHEMBL21190604 | 0.91 | PPARG (0.56) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4725479-A1 | PPAR AGONISTS FOR TREATMENT OF DISEASES ASSOCIATED WITH AATD | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-15 | — | — | EP | claimed |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2026-03-10 | — | — | US | claimed |
| EP-3792249-B1 | PHENYL AMINO SODIUM PROPIONATE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) | 2025-09-24 | — | — | EP | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2025011750-A1 | COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | Université Toulouse III - Paul Sabatier (FR) | 2025-01-16 | — | — | WO | claimed |
| EP-3858346-B1 | CHIGLITAZAR FOR USE IN THE TREATMENT OF FIBROSIS | SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) | 2024-12-25 | — | — | EP | claimed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | claimed |
| US-12064416-B2 | Pharmaceutical combination containing glucose kinase activator and PPAR receptor activator, composition, compound preparation method for same, and uses thereof | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2024-08-20 | — | — | US | claimed |
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | claimed |
| EP-4188378-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | The Governors of the University of Alberta (CA) | 2023-06-07 | — | — | EP | claimed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | claimed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | claimed |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-02-23 | — | — | US | claimed |
| EP-4135691-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-02-22 | — | — | EP | claimed |
| US-11519034-B2 | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | GENFIT (FR) | 2022-12-06 | — | — | US | claimed |
| CN-115397412-A | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2022-11-25 | — | — | CN | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 431/4885PPARA 1378/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 467/4885PPARA 1336/4885 |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | SYNJ1, MYT1, SYNJ2 | PPARG 140/4885PPARA 174/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 431/4885PPARA 1378/4885 |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 431/4885PPARA 1378/4885 |
| US-12064416-B2 | Pharmaceutical combination containing glucose kinase activator and PPAR receptor activator, composition, compound preparation method for same, and uses thereof | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885 |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 431/4885PPARA 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.